Table 4

Summary of systemic and mucosal immune responsesc

Dosage cohortSystemic responses in serumaMucosal responses
ASCbALSaFecala
IgAIgGIgAIgGIgAIgGIgA
5 μgd6.442
25 μge22.1
28.87.714.826.2ND
50 μgf48.860.64626.82
11.832.23.8258.5
25.116.52326.999
8.314.3184321.618.2123.1
4.46.963.3
2
24.29.62424.8
9.18.31934.6
7.5
106.743.822152.4
100 μgg28.440.15.7
30.520.213924.453.951.2
37.5130.91917.45.84.9
4.416.0
24.447.31631010787.833
  • a Peak fold increase above baseline.

  • b SFC/106 cells.

  • c –, a negative response for that assay; ND, not done (the baseline was not available for calculating the fold increase).

  • d Four of 5 (80%) were complete nonresponders.

  • e Four of 6 (67%) were complete nonresponders.

  • f Two of 12 (17%) were complete nonresponders.

  • g Seven of 12 (58%) were complete nonresponders.